Sanofi's amlitelimab achieves primary endpoint in mid-stage atopic dermatitis study

Sanofi SA SNY says its Phase 2b (STREAM-AD) study of amlitelimab for adults with moderate to severe atopic dermatitis who cannot adequately manage their condition with topical medications, has achieved its primary endpoint goals.

This represents the 5th positive result for Sanofi's pipeline since the start of 2023.

Amlitelimab has shown statistically significant improvements in signs and symptoms of moderate to severe atopic dermatitis in adults.

Also read: Sanofi's $3 billion acquisition of Provention Bio hits regulatory hurdle: FTC requests more information.

Amlitelimab treatment resulted in statistically significant improvements in mean Eczema Area and Severity Index (EASI) score from baseline at 16 weeks compared to placebo for the four subcutaneous doses studied.

Improvements were also seen in key secondary endpoints at 16 weeks.

Primary and secondary outcomes showed continued improvements through week 24.

Biomarker results suggest impact on both type 2 and non-type 2 pathways.

Amlitelimab was well tolerated in all dose arms of the study, and no new safety issues were detected.

Amlitelimab is a fully human, non-depleting monoclonal antibody that binds to OX40 ligands.

The detailed efficacy and safety results of this trial will be presented at a future scientific forum.

Price Action: SNY shares are down 0.34% at pre-trade $53.30 when last checked on Tuesday.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.